Krave Kratom Review: I Read the Class Action So You Do Not Have to Take Anyone's Word
Kemal WhyteThe numbers first. If someone is difficult to wake, is not breathing normally, is having a seizure, or is unresponsive, call 911. Poison Control is 1-800-222-1222, around the clock, for a reaction that worries you. Call or text 988 anywhere in the United States. The federal treatment locator is findtreatment.gov.
Stated once. Kratom is not a treatment for opioid use disorder, and it is not a treatment for opioid or kratom withdrawal. The medicines with an evidence base are buprenorphine, methadone and naltrexone, and they come from a clinician. Clinical questions belong with a clinician, not with a seller.
Listen to this column
Read by an AI voice. The words are mine, the voice is not. The whole column is read aloud, including the numbers above, the four boxes below and every disclosure about my own companies. The catalog table is pointed to rather than read, because it is a grid. Case and docket numbers are read out digit by digit.
Checked October 19, 2026. In the class action, No. 3:24-cv-00311 in the Southern District of California, the parties told the court on July 28, 2026, that they had reached a settlement in principle; the docket showed no dismissal on October 19, 2026, and no class was certified in anything I read. California's suit was announced on May 1, 2026; I found no case number and no outcome.
Next check: when the federal case is dismissed, when California's case produces an order, and on January 19, 2027.
Who wrote this, and what we sell. Checked October 19, 2026. Written by Kemal Whyte, founder and CEO of Rebel X Brands. This site sells nothing; my companies do. Rebel X wholesales GRH Kratom, GUD Tonics and King K, including King K liquid kratom extracts and Rush kratom shots, which compete with Krave's shots. GRH Kratom's retail store sells those brands and others, MIT45 among them. No store in my group sells Krave or any product from its company. Krave did not commission or pay for this column and has not seen it. There are no affiliate links. I am not affiliated with or endorsed by Krave, and its names are its trademarks. Corrections go through the contact page on kemalwhyte.com. Next review January 19, 2027.
How I reviewed it. Documents only, read on October 19, 2026. I did not buy, taste, dose or lab-test anything Krave sells. The sources are kravekratom.com and the pack images it publishes, the federal court's orders and dockets, classaction.org, California's releases and complaint, FDA's 2018 letter to the company, and the American Kratom Association's GMP list. No stars, no scores.
Search "krave kratom" and the second result, when this was checked on October 19, 2026, is a classaction.org page whose headline reports a class action claiming Krave Botanicals misled consumers about highly addictive kratom products. Anyone who clicks it could take it for the case still on the court's docket. It is not. Its plaintiffs dropped that case in 2023.
The other case was filed in February 2024. Its judge twice let the core claims go forward and sanctioned the company over a deleted blog; in July 2026 the parties reported a settlement in principle. In May 2026 California announced a suit of its own. The short version: plenty of paperwork about the company and very little from it about what is in the bottle.
Quick verdict, in words. What the documents show: 52 products, from leaf powder to extract shots, listed at $7.99 to $149.99; one 2024 class action whose core claims survived two motions to dismiss, with a sanctions order, no class certified, and a settlement in principle the parties reported in July 2026; and a civil suit by the State of California. What is missing: any certificate of analysis, named laboratory, lot number or mitragynine figure on its site. Who would want more: anyone who wants to know what is in a Krave product, or what the "100X" on a shot multiplies.
The Krave Kratom lawsuit on page one was dropped in 2023
The classaction.org article, published on April 17, 2023, and last updated on January 30, 2026, covers No. 3:23-cv-00669 in the Southern District of California, filed on April 13, 2023, under California's Unfair Competition Law and Consumers Legal Remedies Act. By its account, the complaint said the leaf logo and "All Natural" packaging misled buyers about addictiveness, that the website was "rife with praise for kratom", and that the only warning was a line saying kratom's addictive potential was still being researched.
The federal court later recorded that the 2023 plaintiffs "voluntarily dismissed their claims with prejudice on June 23, 2023, and August 14, 2023" (the same order also gives August 13), and that "The 2023 case was never adjudicated on the merits." It still matters, because the sanctions order below turns partly on it.
The kratom class action lawsuit filed in 2024
The 2024 case is No. 3:24-cv-00311-GPC-MSB, filed on February 16, 2024, before District Judge Gonzalo P. Curiel, against Ashlynn Marketing Group, Inc., which a federal docket describes as doing business as Krave, Krave Kratom and Krave Botanicals. Two related cases, one transferred from New York, were consolidated with it, and a consolidated complaint followed on March 7, 2025. Four plaintiffs proceed under initials.
The court's summary: "Plaintiffs essentially allege that Defendant failed to disclose kratom's addictiveness to consumers before they purchased Defendant's kratom products." They say the packaging is "woefully sparse", with "a bog-standard disclaimer stating that the Products are not regulated or evaluated by the FDA", that the company received user reports about kratom's addictive potential, and, on information and belief, that growers and distributors in Southeast Asia disclosed its addictive nature to the company. The claims are California's UCL and CLRA, New York's General Business Law sections 349 and 350, and fraudulent omission. Alleged, all of it. None of it tried.
What the judge has decided, and what he has not
On a motion to dismiss, a court takes the allegations as true. Nothing below is a finding about Krave's products.
On September 20, 2024, the court let the CLRA and fraud claims proceed. The UCL and False Advertising Law claims went, without prejudice, for want of equitable jurisdiction in federal court; implied warranty and unjust enrichment went for good, as out of time. That order holds the line most likely to be misquoted: "The Court finds these allegations sufficient to show that Defendant's kratom products pose an unreasonable safety risk." The operative words are "these allegations".
On July 1, 2025, in its second ruling on dismissal, the court threw out the nationwide class claims without leave to amend and struck those allegations, because consumer protection and fraudulent omission laws differ too much between states for common legal questions to predominate. Everything else survived. The California and New York classes remain proposed. The plaintiffs have since moved for class certification, an order of March 13, 2026, records. On May 1, 2026, the court vacated the hearing on it pending private mediation. No class was certified in anything I read.
The passage every seller should read rejects the preemption defense: "a disclosure that a supplement has addictive qualities is not a 'claim to diagnose, mitigate, treat, cure, or prevent' disease." On October 16, 2025, the judge refused to reconsider, adding that "Congress' purpose in regulating the labeling of supplements was not to shield manufacturers from liability for failing to warn of the addictive nature of a supplement".
Read that narrowly. The court did not find kratom addictive, and it ordered no warning. It said a warning would not break the federal labeling rules.
My view, and only mine: if a warning is not a forbidden disease claim, leaving it off is a choice a seller has to defend on its own merits. That includes my companies.
The deleted blog, the sanctions, and a settlement in principle
On April 28, 2026, the court granted in part a motion for sanctions over "a blog that was previously hosted on Defendant's website, KraveKratom.com". According to the sanctions order, an outside contractor, Jet Rank, wrote and published it, and its topics included "Kratom for Pain Management". The company says the posts were deleted "on or around July 2023" and that no archive exists.
In May 2023, while the earlier suit was pending, by the parties' accounts an FDA investigator visited to flag unidentified blog content, though "The FDA did not order Defendant to delete all blog content". I found no FDA document about that visit. And the court took judicial notice that the blog was publicly available on April 20, 2025, and not on October 9, 2025.
Then the findings. "Defendant plainly had a duty to preserve evidence related to the previous class action ... and violated that duty by ordering the deletion of all blog materials in July 2023 while that case was still ongoing." And: "The Court finds that the ESI in question was spoliated by Defendant, and that intent may be inferred from the record."
But the court chose the lighter measures of Rule 37(e)(1) over 37(e)(2). At any trial, the plaintiffs may offer archived Wayback Machine pages and the jury will be told they are authentic, and that the company had a duty to preserve the blog, which was removed from the website, without preserved copies, after that duty attached. The plaintiffs were also held entitled to their fees and costs for the motion. And "the instruction will not inform the jury that it can or must infer that the lost evidence was favorable to Plaintiffs."
I will not guess at anyone's reasons; the order says what it says. Whether any of the blog is back, I could not establish.
On July 28, 2026, both sides told the court that at a mediation on July 14 they "reached a settlement in principle that will fully resolve this Action", and that they "anticipate stipulating to dismissal" once a long-form agreement is signed. I have not seen the terms or the later filings, the last on October 19, 2026, when the docket showed no dismissal. A settlement in principle is not a ruling on the claims.
California's own lawsuit
On May 1, 2026, the California Department of Public Health announced that it and Attorney General Bonta had sued "Ashlynn Marketing Group, Inc., doing business as Krave, Krave Kratom, and/or Krave Botanicals" in San Diego County Superior Court, "for repeatedly manufacturing and distributing adulterated and illegal kratom-derived food products and for interfering with a CDPH embargo in violation of state law."
The rest is the state's account. In May 2025 inspectors at the company's Santee facility "found kratom powders, capsules, liquids, and chewable tablets being manufactured and held for sale", and embargoed all kratom materials on site. Visits in October 2025 and April 2026, CDPH says, collected evidence that indicated embargoed products "had been moved, tampered with and repackaged." CDPH says: "The firm's owner continues to manufacture kratom products and ships orders weekly." It wants manufacture stopped, the embargoed stock destroyed, "Civil penalties of up to $1,000 per day for each violation", and its costs.
Krave's online catalog lists no tablets, and the release does not say whose name was on those. I found no case number and no ruling. These are allegations.
What Krave Botanicals sells, and what it says about it
Krave's catalog listed 52 products on October 19, 2026. Prices are as listed on kravekratom.com on that date. The leaf rows show the Bali sizes; the archive gives the same price range for every strain name.
| Format | What is listed | Price as listed | Mitragynine stated? |
|---|---|---|---|
| Leaf powder | Bali and other strain names, 60 g to 1,000 g | $19.99 (60 g), $29.99 (120 g), $49.99 (250 g), $69.99 (500 g), $99.99 (1,000 g) | No. |
| Leaf capsules | The same strain names, 30 to 1,000 capsules; fill weight not stated | $12.99 (30), $24.99 (75), $39.99 (150), $59.99 (300), $79.99 (500), $149.99 (1,000) | No. |
| Flavored powder | Dragon Fruit, Juice Bana, Passion Fruit, Sweet Tea; size not stated | $9.99 each | No. |
| Liquid shots | Six strain names; volume not shown | $9.99 each | No. |
| Krave 100X shot | No volume stated on its page | $19.99 | No. |
| Krave 200X shot | 10 mL on the front image | $24.99 | No. |
| Jule Kratom Extract | Six flavors; 10 mL on the Natural flavor's front image | $7.99 each | No. |
| Extract capsules | Two-capsule packs in six strain names; an "Ultra Enhanced Indo" three-capsule blister; a five-capsule blister; 100 hybrid capsules | $8.99; $29.99; $39.99; $29.99 | No. |
| Hybrid extract powder | Size not stated | $29.99 | No. |
Krave's words for it are "Premium Quality Kratom", "AUTHENTIC 100% genuine kratom products", and "All Natural" on most front labels I saw; the 100X page calls it "the best concentrate". Every product description I read carries the same block, including "THIS PRODUCT CONTAINS: MITRAGYNA SPECIOSA**", the asterisks explained as "Not deemed fit for human consumption by FDA". That is Krave's wording, not FDA's. None of the descriptions checked uses the words addiction, dependence, habit or withdrawal.
My arithmetic: Bali powder runs from $0.33 a gram in the 60 g bag to $0.10 in the 1,000 g bag, and Bali capsules from $0.43 each to $0.15, fill weight unstated. The 200X and the Jule Natural both say 10 mL. One costs a little over three times the other, and nothing Krave publishes says why.
No certificates, no milligrams, and a hundred times what?
Krave's WordPress page list has 16 entries, and none is for lab results. No certificate of analysis, no laboratory named, no lot number. No listing states mitragynine per serving or per unit, and none of the front-of-pack images I read shows a milligram figure. Krave publishes no backs of packs, so I cannot speak to those.
So there is no price per 100 mg of mitragynine to work out, and no honest strength comparison with anyone. "100X" and "200X" are names. No document I read says what is multiplied, or that either is stronger than a Jule. Krave makes no testing claim, so its silence is consistent. It is still silence. If Krave publishes a lot-specific certificate from a named laboratory, send it to me.
The paperwork around the edges
FDA. The only FDA warning letter to the company I found is dated July 26, 2018, from the Center for Tobacco Products to the company "d/b/a Imperial Smoke", and it concerns a hookah filter, not kratom. Company history, nothing more. I found no FDA letter, recall or advisory about Krave's kratom.
AKA. Krave and its company are not on the American Kratom Association's GMP Qualified Vendors list as read on October 19, 2026. Krave claims no such listing, so the absence contradicts nothing it says. GRH Kratom, King K and GUD Tonics are not on it either, as I wrote on October 1, 2026.
Shipping. Krave's footer says: "We do not ship to the following states: Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin." San Diego and Oceanside are excluded as cities, but California is not on the state list. The company's facility is in Santee, and the state health department said in a release dated January 16, 2026 that "Kratom-derived products and 7-OH are illegal to manufacture or sell for consumption". Whether checkout blocks a California address, I do not know; no order was placed.
Age and terms. The footer and the product pages say 21. The terms say "You must be 18 or older to use our website." They send disputes to "confidential arbitration in California", then say "Any disputes will be handled in the EU"; which clause wins is a lawyer's question.
Affiliates. Krave invites affiliates to "earn commission on each successful sale you refer" and publishes no rates. Before trusting a Krave Kratom review elsewhere, check who is paid when you click, a case I made against my own companies too in most kratom reviews are advertising.
Where my own house is no better
A seller writing about another seller's lawsuit owes you his own exposure. GRH Kratom sells MIT 45 products, and GRH's own product pages note a class action against MIT45 in the same district "concerning disclosure of dependency risk on concentrated extracts". I am not reading one case into the other. On paperwork, our certificates for the King K extracts and our Boost blend carry no heavy-metal or microbial panel, and King K's lab-results address redirects to its homepage. Ours are not complete either.
One of my own pages says more than my paperwork does. Rebel X's extracts collection calls every batch "lab-tested with a COA, AKA-GMP aligned", and says each extract batch ships with a third-party certificate "covering the alkaloid profile, heavy metals, microbials, and residual solvents". Neither AKA's list nor our certificates support that as written, and the page is mine.
One more filing, which I will only put beside my own history. A July 2025 class complaint in the Central District of California, No. 2:25-cv-06491, sued Krave's company as "doing business as SE7EN" and alleged that it sold 7-OH tablets and shots under that name, while saying its raw kratom, sold "primarily under the brand name Krave", was not the subject of the suit. It was dropped on October 7, 2025, without prejudice, and never decided. I found no Se7en site, trademark or product page tying the name to the company, and Krave's catalog lists no 7-OH product. Beside that allegation sits a fact: Rebel X, my wholesale company, sold the Tier Seven 7-OH line until July 30, 2026, and the Tier 7 certificate is still on our CDN.
Now put my companies through this column's two sharpest tests. Our product copy on King K, GUD Tonics and Rebel X carries no addiction or dependence warning, which is the omission the Krave suit alleges; on GRH, such words appear only in notes about other brands, and I have not checked our physical labels. The shipping policies on GRH, King K and GUD Tonics, like Krave's, exclude San Diego and Oceanside but not California. And KING K PRIME, an extract tablet, is purchasable on grhkratom.com.
Questions about Krave Kratom and its lawsuits
Is Krave Kratom being sued?
Yes, in two cases I found. A consumer class action, No. 3:24-cv-00311 in the Southern District of California, alleges that the company failed to disclose kratom's addictiveness; on July 28, 2026, the parties reported a settlement in principle, and no dismissal was on the docket on October 19, 2026. California's health department and Attorney General announced their own civil complaint on May 1, 2026. Both are allegations.
Is the classaction.org Krave Botanicals case the same lawsuit?
No. That page covers No. 3:23-cv-00669, filed on April 13, 2023. The federal court later recorded that its plaintiffs voluntarily dismissed their claims with prejudice in June and August 2023, and that the case was never adjudicated on the merits.
What has the court decided in the kratom class action lawsuit against Krave?
It let the CLRA and fraud claims proceed in September 2024, struck the nationwide class allegations in July 2025, held that an addiction warning would not be a disease claim, refused to reconsider in October 2025, and in April 2026 sanctioned the company over its deleted blog with lesser Rule 37(e)(1) measures. I found no ruling on class certification; in July 2026 the parties reported a settlement in principle.
Does Krave publish lab results or mitragynine content?
Not in anything read on October 19, 2026. There is no lab-results page, no named laboratory, no lot number, and no mitragynine figure on any listing or front-of-pack image read.
Did the court find that Krave products are addictive?
Not in any order I read. Rulings on motions to dismiss treat the allegations as true. The preemption rulings say an addiction warning would not be an unlawful disease claim; they do not find kratom addictive, and they do not order a warning.
What would change my read
Three documents would. The settlement or dismissal papers in the federal case. Any order or settlement in California's case. A lot-specific certificate from Krave. Until I can read one of them, a review that tells you Krave has lost its class action, or that its products are clean, is telling you something the record does not.
The habit I keep arguing against, here and in my column on what the kratom death numbers count, is letting a phrase travel without the document it came from. "Unreasonable safety risk" without "these allegations". "Spoliated" without "Rule 37(e)(1)". If a sentence here has lost its document, tell me and I will correct it at the top, with the date.
Disclaimer: This column describes public documents as they read on October 19, 2026. Dockets and listings change. Allegations are allegations, and rulings on motions to dismiss are not findings of fact. It is general commentary, not legal or medical advice. Opinions are the author's own; the author holds commercial interests in botanical brands. Naming a brand implies no affiliation with it or endorsement by it. Nothing here is a health claim, and statements about botanical products have not been evaluated by the Food and Drug Administration.